GC
VRTX icon

Guidance Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Guidance Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
2,211
+304
+16% +$135K 0.23% 104
2026
Q1 		$809K Buy
1,907
+110
+6% +$51.3K 0.18% 122
2025
Q4 		$840K Buy
1,797
+167
+10% +$72K 0.21% 112
2025
Q3 		$687K Sell
1,630
-313
-16% -$131K 0.18% 129
2025
Q2 		$898K Sell
1,943
-332
-15% -$153K 0.26% 92
2025
Q1 		$1.14M Buy
2,275
+174
+8% +$81.1K 0.35% 53
2024
Q4 		$924K Buy
2,101
+395
+23% +$183K 0.28% 71
2024
Q3 		$824K Buy
1,706
+150
+10% +$72.1K 0.26% 95
2024
Q2 		$771K Buy
1,556
+149
+11% +$64.7K 0.25% 89
2024
Q1 		$559K Buy
1,407
+24
+2% +$10.1K 0.21% 109
2023
Q4 		$568K Buy
1,383
+312
+29% +$115K 0.23% 98
2023
Q3 		$370K Buy
1,071
+49
+5% +$17.1K 0.17% 108
2023
Q2 		$358K Buy
+1,022
New +$344K 0.16% 116

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Guidance Capital's VRTX Position: Q2 2026 in Review

Guidance Capital increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, buying an estimated $135K and bringing the position to 2,211 shares worth $1.07M. The position accounts for 0.23% of the portfolio, ranked #104.

Guidance Capital first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.14M in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Guidance Capital held 2,211 shares of Vertex Pharmaceuticals worth $1.07M as of Q2 2026.
  • Guidance Capital bought 304 Vertex Pharmaceuticals shares in Q2 2026, an estimated $135K.
  • Vertex Pharmaceuticals made up 0.23% of Guidance Capital's portfolio in Q2 2026, its #104 holding.
  • Guidance Capital first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Guidance Capital's Vertex Pharmaceuticals position peaked at $1.14M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Guidance Capital's 13F filing for Q2 2026, filed 20 Jul 2026.